Anderson Algorithm equals better results for ovarian cancer patients
A MESSAGE FROM
RON DEPINHO, M.D.

THE MD ANDERSON CANCER CENTER
BOARD OF VISITORS (BOV) is a driving force in support of our mission to end cancer. This impressive volunteer group of business and community leaders from around the globe supports our world-class faculty and staff in their efforts to provide the best patient care possible today and to conduct the most impactful research offering new hope for tomorrow. The passion and commitment of our BOV inspire me every day.

Illustrating the BOV’s crucial role in our mission are three new faculty awards, made possible by the generosity and foresight of:

• BOV member Bill Finneran, who has established the Finneran Family Prize in Translational Research to honor leading translational cancer research, which turns basic science breakthroughs into novel cancer therapies.
• BOV member Jack Randall and his wife, Beverly, who have established the Jack and Beverly Randall Prize for Excellence in Cancer Research to encourage creativity and ingenuity in the clinic and in the research lab.
• BOV member Gary Stein, along with his family and fellow BOV member Regina Rogers, who have established the Shirley Stein Scientific Endowed Research Award to recognize innovative clinical research that excels despite limited resources.

On behalf of our team of cancer-fighting champions and the patients and families we serve, I extend my sincere gratitude for this significant philanthropic support, reflecting utmost confidence in our gifted and devoted faculty. You can read more about these gifts and the inaugural recipients on pages 6-7.

I’m profoundly grateful to all who join with MD Anderson to help extend and improve the lives of cancer patients everywhere. Together, we are Making Cancer History®.

PROMISE

The University of Texas MD Anderson Cancer Center Development Office • Unit 106
P.O. Box 301439 • Houston, TX 77230-1439
713-765-3660 • 800-525-5841
mdanderson.org/gifts • promise@mdanderson.org

Ron DePinho, M.D.
President
Dan Fontaine
Executive Chief of Staff for Institutional Advancement
Patrick B. Mulvey
Vice President for Development
Sarah Newson
Associate Vice President for Communications
Jim Newman
Director, External Communications
Sarah Watson
Program Manager, Editor, Development Communications
Marly Jacob
Senior Communications Designer
Miriam Spradling
Communications Specialist, Assistant Editor
Contributing Writers
Dave Bellows, Ron Gilmore, Allison Ignacio, Bob Kaufman, Scott Merville, Miriam Spradling, Delia Stroud

ON THE COVER:
A new algorithm can make ovarian cancer surgeries more successful, says Anil Sood, M.D. Story on page 3. PHOTO BY JOHN SMALLWOOD

FUN IN THE SUN

PGA TOUR Wives Association hosts outing for pediatric patients

It’s official: MD Anderson is the cancer center of the PGA TOUR. The partnership, announced at the Shell Houston Open at the Golf Club of Houston, will expand efforts to reduce skin cancer risk among golf fans and players. To celebrate, the PGA TOUR Wives Association and MD Anderson hosted an activity for pediatric cancer patients and their families. Fun in the Sun, at MD Anderson’s shaded pavilion on the 18th green, featured beach party games, face painting, crafts and a healthy lunch.

www.youtube.com/mygivingtompdanderson

CPRIT AWARDS MAJOR ALLOTMENT TO MD ANDERSON

BY RON GILMORE

MD ANDERSON has received more than $22 million in research grants from the Cancer Prevention and Research Institute of Texas (CPRIT). Approximately half of the funds awarded across the entire state for Individual Investigator Research Awards (IIRA) went to MD Anderson faculty. Additionally, 40% of total IIRA awards include those for children’s and adolescent cancer, early detection and prevention.

The CPRIT awards will go toward studies in breast, skin, prostate, pancreas, colon and lung cancers in adults; leukemia and brain cancer in children; and studies aimed at preventing colon and lung cancers. Immatics Biotechnologies was one of four Company Formation Awards funded by CPRIT. At more than $19 million, the project will further translate MD Anderson’s immunotherapy knowledge into new therapeutics for cancer patients.

The institution has received $215 million in total awards since CPRIT was founded in 2009.
Jim Allison, Ph.D., chair of Immunology, has received the 2015 Paul Ehrlich and Ludwig Darmstaedter Prize. “This award is special to me because it’s named for Paul Ehrlich, the German scientist who was the first to suggest immune system surveillance of cancer more than 100 years ago,” says Allison. Allison pioneered the immune checkpoint blockade approach to treating cancer by blocking molecules that act as a brake on T cells, the immune system’s customized attack cells. The resulting drug, ipilimumab, has extinguished previously untreatable late-stage melanoma in an unprecedented 22% of patients for at least 10 years.

The U.S. Food and Drug Administration approved the drug for metastatic melanoma in 2011. Since that time, ipilimumab and additional new drugs that impede other checkpoints have been applied to lung, bladder and kidney cancers with promising early results.

Allison shares the prize with Carl June, M.D., University of Pennsylvania, who pioneered an approach that customizes T cells to attack leukemia.

A SURGICAL ALGORITHM developed by MD Anderson ovarian cancer specialists dramatically increases the frequency of complete removal of all visible tumor — a milestone strongly tied to improved survival.

The researchers describe the algorithm in the journal Nature Reviews Clinical Oncology. “Our algorithm allows us to be much smarter about whom we operate on up front, providing a more individualized approach to surgery that’s led to better results for our patients,” says Anil Sood, M.D., professor of Gynecologic Oncology and Reproductive Medicine and senior author of the paper.

The multi-step process was developed through MD Anderson’s Moon Shots Program (see page 4). Sood is co-leader of the Breast and Ovarian Cancers Moon Shot.
PLATFOMS TO SUCCESS
Vital infrastructure and expertise convert ideas into results
BY SCOTT MERVILLE

SIX MOON SHOTS have taken flight on their mission to significantly reduce deaths from cancer. MD Anderson’s Moon Shots Program has assembled an empowering infrastructure of expertise and technology to help accelerate their efforts.

Ten moon shot platforms — think of them as research engines — provide resources and brainpower to more efficiently gather and use data. The platforms also specialize in the development of new treatments and innovative prevention methods to reduce cancer’s toll (see sidebar).

“These platforms will help address areas at the cutting edge of science and medicine,” a panel of outside experts from other major cancer centers noted after a December review. Areas cited by the Scientific Advisory Board include drug development, prevention, cancer genetics and proteomics, preclinical cancer models, and the storage and processing of clinical and research information.

Coupled with the institution’s world-leading clinical trials engine, the platforms position the institution to better match novel drugs to appropriate patients and to enhance its research-driven care by learning more from each patient.

“The idea is to have each patient contributing to and benefiting from research, with the goal of improving outcomes and accelerating cures,” says Andy Futreal, Ph.D., Moon Shots Program co-leader.

VITAL INFRASTRUCTURE

PLATFORMS

MOON SHOTS PROGRAM OVERVIEW

MD Anderson’s Moon Shots Program comprises six teams of researchers and clinicians initially focusing on these eight cancers:

• Acute myeloid leukemia/myelodysplastic syndromes
• Chronic lymphocytic leukemia
• Melanoma
• Lung cancer
• Prostate cancer
• Triple-negative breast and high-grade serous ovarian cancers

Each moon shot team is pursuing innovative projects prioritized for greatest patient impact, from basic and translational research to biomarker-driven clinical trials. Specialized platforms provide infrastructure, systems and strategy.

As of March 31, private philanthropic commitments to the program total more than $282,770,449.

www.cancermoonshots.org

#MOONSHOTS

PLATFORMS

MOON SHOTS PROGRAM PLATFORMS

IMMUNOTHERAPY
Conducts preclinical studies and clinical trials to evaluate novel immunotherapies as single treatments or combined with other drugs.

Leaders: Executive Director Jim Allison, Ph.D., chair, Immunology; Scientific Director Padmanee Sharma, M.D., professor, Genitourinary Medical Oncology

CANCER GENOMICS LABORATORY
Provides rapid, high-quality genomic sequencing services and access to genomic data.

Leaders: Kenner Shaw, Ph.D., executive director; Maggi Morgan, scientific manager, the Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy; Andy Futreal, Ph.D., professor and interim chair, Curtis Gumbs, scientific manager, Genomic Medicine; Janhui “John” Zhang, Ph.D., associate director, Bioinformatics, Institute for Applied Cancer Science

PROTEOMICS
Sifts through thousands of cancer-related proteins to find those useful for diagnosis and imaging or as treatment targets.

Leader: Sam Hanash, M.D., Ph.D., director, the Red and Charline McCombs Institute for the Early Detection and Treatment of Cancer

By Scott Merville

The moon shot platforms are generating new opportunities, including deeper collaborations with biotech and pharmaceutical companies.

Amgen, for example, is developing a unique drug that connects killer immune system T cells to cancer cells. When the company contacted Guillermo Garcia-Manero, M.D., professor of Leukemia and leader of the Myelodysplastic Syndromes/Acute Myeloid Leukemia Moon Shot, asking for patient samples, Garcia-Manero had something bigger in mind.

His moon shot has deep ties with the proteomics platform, led by Sam Hanash, M.D., Ph.D., professor of Clinical Cancer Prevention. The platform exhaustively screens and characterizes the tens of thousands of proteins active in cancer cells to identify targets for drugs or indicators for screening and diagnosis.

Hanash and Garcia-Manero, along with Ferran Prat, Ph.D., J.D., vice president for Strategic Industry Ventures, joined in talks with Amgen. What might have been a simple sharing of samples or a basic clinical trial blossomed into “a really exciting collaboration to discover and validate novel targets, generate new drugs, test them pre-clinically and take them to patients,” says Prat.

The interest of such companies — the Amgen deal is one of several in the past year — validates what the Moon Shots Program is trying to achieve. The collaborations provide early access to drugs in development and enable studies to clarify how to treat patients with new therapies. In addition, thanks to the philanthropy supported platforms, these industry alliances are providing new sources of research support.
FINDING JOY
IN EVERYDAY MOMENTS

Lung cancer survivor thankful to MD Anderson for renewed richness of life

BY MIRIAM SPRADLING

Back in the ’90s, Reba Kennedy made it her mission to leave no stone unturned when it came to her cancer treatment. Now she hopes MD Anderson’s Lung Cancer Moon Shot will encourage others to follow her lead.

Surgeons in Kennedy’s hometown of Knoxville, Tenn., removed her first lung cancer in 1997, her second in 1999 and a breast cancer in 2002. Two years later, her lung cancer returned, this time stage IV, in a large mass wrapped around her ribs. Kennedy’s doctors deemed the tumor inoperable and recommended she seek a second opinion at MD Anderson.

“I was facing death,” she recalls. “But from the time I came through the door, everybody was fighting for me. I knew I was going to the best place in the world.”

Anne Tsao, M.D., associate professor, Thoracic/Head and Neck Medical Oncology, and David Rice, M.D., professor, Thoracic and Cardiovascular Surgery, determined they could remove the tumor if they replaced part of Kennedy’s rib cage with an artificial one.

“Getting this opportunity felt like the biggest present in the world,” she says.

‘Give it everything you’ve got’

The past decade has been eventful. Both of Kennedy’s sons have married and had two children of their own. She water skis, plays golf, tubes down snowy mountains with her grandchildren and recently zip-lined in Costa Rica.

“Every day is the best day ever,” she says. “There’s a rich segment of my life that I wouldn’t have had if I hadn’t gone to MD Anderson. I couldn’t be more grateful.”

Kennedy is confident the Lung Cancer Moon Shot will promote new therapies, give hope and encourage patients around the world to get up and fight.

“It’s as if I’ve been granted a whole new life, and I’d love for other patients to have that too,” she says. “I tell people, ‘Don’t give up. Don’t give in. You need to go to the best doctors in the world, see what they’ve got to say, then give it everything you’ve got.’

I’ve found so much joy in everyday life that I hadn’t really acknowledged until I almost lost the chance. Sometimes people hear they’re at the end of the road and give up, but they need to know there is hope.

MIRACLES DO HAPPEN.
MD Anderson gave me the strength to get up and fight. The doctors there are absolutely battling cancer for us all.”

—REBA KENNEDY

What’s your moon shot? Contact us at promise@mdanderson.org and tell us why MD Anderson’s Moon Shots Program is important to you.

www.youtube.com/mygivingtomdanderson

LEARN MORE AT www.mdanderson.org/gifts
PRESIDENT’S RECOGNITION FOR FACULTY EXCELLENCE

BY ALLISON IGNACIO

The President’s Recognition for Faculty Excellence program, held each February, honors faculty members whose exceptional efforts have brought distinction to MD Anderson. This year marked the announcement of three new awards, funded through endowments established by generous members of the MD Anderson Cancer Center Board of Visitors.

Treating the patient as well as the cancer

Finneran Family Prize recognizes leadership and innovation

For Bill Finneran, MD Anderson represents one thing: family.

“It doesn’t feel like a hospital,” he says. “It’s a family and it feels like it.”

Finneran was diagnosed with prostate cancer 20 years ago. When looking back at his time as a patient, Finneran doesn’t focus on his diagnosis. It’s his relationships with doctors, faculty and staff he recalls most.

“I remember the personal care and attention from the doctors and staff,” says Finneran, a resident of New York and Palm Beach, Fla. “I always found total commitment on every level of patient care as well as the highest quality of research.”

Now a member of the MD Anderson Cancer Center Board of Visitors, he’s also found a way to honor those he believes hold the key to ending cancer for good.

The Finneran Family Prize will be bestowed annually to a deserving faculty member through the Finneran Family Endowment for Translational Research at MD Anderson.

Established through a $1 million gift announced at the 2013 Making Cancer History® Gala in Palm Beach, the inaugural prize was awarded to Christopher Logothetis, M.D., professor and chair, Genitourinary Medical Oncology.

“This was a pleasant and quite moving surprise because I’ve had the pleasure of caring for Bill for a long time,” says Logothetis. “He’s a strong-willed, well-intentioned person who knows that his cancer experience has meaning for others as well. He’s allowed us to hone our skills and make sure we treat the patient as well as the cancer.”

Logothetis was recognized for his leadership and innovation in cancer care, particularly as a co-leader of MD Anderson’s Prostate Cancer Moon Shot. He served as Finneran’s primary physician throughout his prostate cancer treatment.

Finneran hopes that the award will inspire MD Anderson faculty for years to come.
More than 40 years of experience in the oil and gas industry have taught Beverly and Jack Randall, co-founder of Jefferies Randall & Dewey, that big ideas get big results.

“It takes creativity, passion and tenacity to have big breakthroughs,” says Jack Randall, a member of the MD Anderson Cancer Center Board of Visitors. “It’s only through truly novel ideas and a willingness to take a chance on the most promising concepts that vision becomes reality.”

It’s that type of thinking that he and wife Beverly hope to stimulate through the Jack and Beverly Randall Prize for Excellence in Cancer Research, established with a large endowment. A cash prize will be awarded each year to an MD Anderson faculty member, with the focus alternating between innovations in cancer research and excellence in patient care.

“We think it’s important to build on MD Anderson’s history of achievement by honoring, encouraging and advancing innovative research,” says Beverly Randall. “This award is our way of supporting tomorrow’s leaders so they have the incentive and resources needed to make this happen.”

Andrew Futreal, Ph.D., the inaugural recipient, is internationally recognized for his groundbreaking research in large-scale systematic cancer genomics. His work has led to the identification of the BRCA1 and BRCA2 breast/ovarian cancer susceptibility genes and BRAF mutations in melanoma. Now, he’s focusing on building a better way to collect and use research.

“We want to provide an engine that will allow almost every patient to contribute to our research and potentially benefit from that research,” says Futreal, adding that the best part of winning the prize is what it stands for.

“It’s meaningful to be recognized for ideas that pushed at the edges of current approaches,” he says. “The idea of alternating the award between researchers and clinicians is exceptional because that’s the way MD Anderson works. It’s a partnership.”

The letter “S” is particularly meaningful for Gary Stein, president of Houston-based Triple-S Steel.

“Our company was named for the three loves of my father’s life: my mother Shirley, his mother Sarah and his sister Sharlene,” says Stein, a member of the MD Anderson Cancer Center Board of Visitors (BOV). “My mom drove the inspiration in our family throughout her entire life.”

Shirley now has another namesake, the Shirley Stein Scientific Endowed Research Award at MD Anderson. The Steins and family friend Regina Rogers, a longtime member of the BOV, established the award with a $600,000 endowment in loving memory of Shirley, who died in October 2013.

“Mom was a force of nature,” says Stein. “She felt strongly that although she never had to be cared for there, that MD Anderson was one of Houston’s crown jewels and needed to be taken care of. This is one way we can honor her memory.”

Another Stein family friend, Gene Landon, M.D., assistant professor of Pathology at MD Anderson, helped inspire the award by shedding light on the need to fund smaller research projects. The Stein endowment will fund two cash awards each year to recognize exceptional clinical research from faculty members with limited project resources.

Alejandro Contreras, M.D., Ph.D., assistant professor of Pathology, and Yun Wu, M.D., Ph.D., associate professor of Pathology, are the inaugural recipients. Contreras focuses on dual imaging of HER2 by immunofluorescence and mRNA in situ hybridization in invasive breast carcinomas. Wu’s research centers on the effect of immune responses to neoadjuvant systemic therapy in triple-negative and HER2+ breast cancer. Both are grateful for the much needed funds.

“When government funding decreases, it’s great to have families who are so philanthropic,” says Contreras. “They allow us to continue the research we believe is so important.”
iPromise

Texas legislators
SEARCH FOR ANSWERS
to ovarian cancer

Foundation presents $50,000 gift inspired by three courageous women

BY MIRIAM SPRADLING

The KK125 Ovarian Cancer Research Foundation, established by State Rep. Ken King (R-Canadian), District 88, and State Rep. Kyle Kacal (R-College Station), District 12, donated $50,000 to ovarian cancer research at MD Anderson. The contribution honors the legislators’ mothers, who both died of the disease in 2013.

“It’s a positive way to project our anger with the horrible disease that took our mothers,” says King, whose mother was treated at MD Anderson. “We must make sure this doesn’t happen to our wives, sisters and friends.”

Kacal describes ovarian cancer as “a dreadful disease with no answers.”

King and Kacal bonded over the loss of their mothers after their freshman year in the Texas Legislature in 2013 and decided to find those answers.

“Where do you go to solve cancer questions? Where are the solutions? They all happen at MD Anderson,” Kacal says. “MD Anderson is where cancers come to die.”

The gift will support research in CA-125, a protein long recognized for its role in predicting ovarian cancer recurrence and that now shows promise as a screening tool for early-stage disease.

The legislators also created the foundation to honor their close friend, the late Andrea Sloan, who was executive director and general counsel for the Texas Advocacy Project until her death from ovarian cancer on New Year’s Day 2014. Sloan also received treatment at MD Anderson.

The representatives, their families, their care teams and Sloan’s family and friends attended a Dec. 15 check presentation at MD Anderson. Ron DePinho, M.D., president, thanked KK125 for its generosity and recognized the extraordinary efforts of the caregivers of the three women who inspired the foundation.

“MD Anderson is where cancers come to die.”

—STATE REPRESENTATIVE KYLE KACAL

Texas Advocacy Project until her death from ovarian cancer on New Year’s Day 2014. Sloan also received treatment at MD Anderson.

The representatives, their families, their care teams and Sloan’s family and friends attended a Dec. 15 check presentation at MD Anderson. Ron DePinho, M.D., president, thanked KK125 for its generosity and recognized the extraordinary efforts of the caregivers of the three women who inspired the foundation.

http://bit.ly/1FD9pio
A GOOD DAY IN CANCER LAND

A team of angels uplifts a triple-negative breast cancer survivor

BY DELIA STROUD

My husband, Jim, and I moved to Houston after living in Philadelphia for 35 years. We love Houston because our children settled here and we have extensive family and friends in the area. But the main reason we’re grateful to live in Houston is that we’re only 20 minutes away from MD Anderson.

For us, 2014 began with a jolt. I had recently retired as an attorney. After having a clear mammogram in June, in January I was diagnosed with “high risk, aggressive, potentially curable” stage III triple-negative breast cancer (TNBC). I never asked, “Why me?” Given the millions struck with cancer, the more appropriate question seemed, “Why not me?”

I hoped to confront the disease with faith, grace, a positive attitude and a sense of humor. The power of prayer, my love of God, family and friends, and MD Anderson have helped me fulfill that goal.

Because I was being treated at a world-class institution, I felt confident I could rely on the expertise of my medical team led by Sharon Giordano (chair, Health Services Research-Clinical), Beth Mittendorf (associate professor, Surgical Oncology), Melissa Crosby (associate professor, Plastic Surgery) and Eric Strom (professor, Radiation Oncology), with my beloved niece, Jennifer Litton (associate professor, Breast Medical Oncology), as an adjunct member. My reliance has been well-placed.

In a 2013 TNBC study, 54% of women who added carboplatin to their chemotherapy regimen had a complete therapeutic response compared with only 40% without the drug. Carboplatin, however, wreaks havoc on blood counts and has potential long-term adverse effects, so MD Anderson hasn’t added it to its standard TNBC regimen. Nonetheless, given my daunting diagnosis, my team offered me that option, which I readily embraced.

I felt I couldn’t lose, and I didn’t. After only two doses of chemo, my tumors had shrunk 90% in the lymph nodes and 70% in the breast. After completing the full course with carboplatin, my lymph nodes were clear and a mere 2% viable tumor remained in the breast.

As my niece Jennifer said, my strong therapeutic response was a “good day in cancer land.” I’ve had many good days because angels doing God’s work abound at MD Anderson. In addition to the gifted doctors and nurses, they include experienced therapists, able technicians, cheerful receptionists and the wonderful cook in the Waterfall Café.

In October, I completed my final radiation, so my active treatment has ended. I hoped cancer would make me a better person. I’m not sure that happened, but I know it’s forged in me a stronger faith in God and stronger relationships with my family and friends. Thanks to MD Anderson, I’m optimistic about my future and supremely grateful.

TNBC is a focus of MD Anderson’s Moon Shots Program (see pages 4-5).

Survivors Say

BOB KAUFMAN is the chief communications and marketing officer for the Texas Department of Transportation. He and his wife live in Austin. Bob was first diagnosed with stage IV non-Hodgkin lymphoma in January 2009.

I’ve always enjoyed an active lifestyle, keen on outdoor sports and healthy living. I competed in high school and college athletics and, as an adult, finished three marathons and a number of shorter races. My family had a history of longevity with little chronic illness. So it came as a huge surprise to my wife and me, when I was diagnosed with stage IV non-Hodgkin lymphoma in January 2009. Following six months of traditional chemotherapy and achieving remission, we were extremely disappointed when the cancer returned a few months later.

In 2010, I became an MD Anderson patient and a candidate for a stem cell transplant. I had the transplant in July 2010, worked hard to get back into good health and am living proof that people can survive and thrive after the fight.

I beat cancer by having the transplant and through the amazing support received from the team at MD Anderson. While the day-to-day management of getting healthy was a challenge, now looking back, it’s a blip in the rearview mirror. Because I feel so blessed to have such a successful outcome, it’s time to tell my story to give others hope and encouragement that they too can succeed. During my journey, a friend shared a phrase that I really like: ‘Every day is a gift, that is why they call it the present.’

Promise invites cancer survivors to share their reflections. Email promise@mdanderson.org.

LEARN MORE AT www.mdanderson.org/gifts
I'm a year since James Ragan died of cancer at age 20. The Corpus Christi native and outspoken advocate against pediatric cancer had raised funds for research since 2007, after his diagnosis of osteosarcoma, a rare bone cancer. Overwhelming community support led James and his sister, Mecklin, to co-found Triumph Over Kid Cancer Foundation in 2010.

“It started as a way to give back to children and families going through what James and our family were enduring,” Mecklin says. “We never could’ve guessed it would get this big, yet we feel we have an opportunity to grow and make a difference.”

At 14, James set his sights on raising $1.5 million to fund pediatric cancer research. His goal came to fruition in December 2013, two months before his death.

“It was something he’d put so much of his time into, and time was something he really valued since he knew he didn’t have a lot of it,” says Mecklin.

Now, the foundation has raised more than $2 million, through widespread grassroots support as well as four annual events in Corpus Christi and New Orleans. MD Anderson matches all of its contributions.

In January, Mecklin and foundation board members Omar Abou-Sayed and Cynthia Coffman presented $367,000 to MD Anderson’s pediatric Genome Research and Sequencing Project. While whole genome sequencing has been promising in adult cancers, it’s rarely done for pediatric cancers due to the cost.

“MD Anderson has a remarkable infrastructure for genomics research through its APOLLO platform (see page 5), so we’ll get to make use of the resources it already has in place,” says Mecklin.

James’ vision was a world without children’s cancer. Mecklin and other foundation board members are determined more than ever to make his dream a reality.

“A friend told me, ‘The hole in your heart will never get smaller, but you can make it feel smaller by growing your own heart bigger every day,’” says Mecklin. “The only way to try to make the pain of losing James go away is to push on until we have enough cures and treatments that there’s no need for foundations like ours. While that’s a lofty goal, it’s definitely a worthwhile endeavor.”

www.triumphoverkidcancer.org

Pediatric cancer foundation continues the vision of its late co-founder
Houston Tri Delta alumnae hosted their inaugural "The Sale" event benefiting MD Anderson Children's Cancer Hospital. The Jan. 10 fundraiser at the Bayou City Event Center attracted 1,200 shoppers and featured apparel from 41 of Houston’s finest boutiques. Each offered end-of-season merchandise at discounted prices. Ticket sales to the event and a preview brunch, combined with the support of generous sponsors, resulted in a $165,000 contribution.

PHOTOS COURTESY OF HOUSTON TRI DELTA

A DECADE-LONG FRIENDSHIP
MD Anderson celebrates 10 years of Making Cancer History® in West Palm Beach

BY MIRIAM SPRADLING

MD Anderson oncologists returned to West Palm Beach Jan. 31 for the institution’s Making Cancer History® educational seminar. Presenters included Ron DePinho, M.D., president; Ernest Hawk, M.D., vice president and division head, Cancer Prevention and Population Sciences; Christopher Logothetis, M.D., chair and professor, Genitourinary Medical Oncology, and co-leader of the Prostate Cancer Moon Shot; and Kelly Hunt, M.D., professor, Surgical Oncology.

More than 130 enthusiastic attendees learned about innovative research in breast and prostate cancers, vital cancer prevention tips and breakthroughs made possible by the Moon Shots Program (see pages 4-5). The seminar raised support for the unprecedented initiative.

The night prior, 75 Palm Beach-area residents gathered at the home of Patrick Park to enjoy a Thanksgiving-themed feast and to learn more about the revolutionary work taking place at MD Anderson.

"It’s our honor to visit Palm Beach and share insight into our fight to end this devastating disease,” DePinho says. “This seminar demonstrates the commitment of several innovative thinkers in the Palm Beach area. We’re thankful for their continued leadership and generous support of our mission. Together, we’re Making Cancer History.”

"This seminar demonstrates the commitment of several innovative thinkers in the Palm Beach area.”
— Ron DePinho, M.D.

LEARN MORE AT www.mdanderson.org/gifts
Online giving is Making Cancer History®

Digital fundraising helps MD Anderson extend its reach and further its mission to end cancer. If you’d like to join the crowd, visit www.mdanderson.org on your laptop, tablet or smart phone and click “You can help: Give now.”

Comments? Suggestions? We welcome your perspective.
Email us your thoughts: promise@mdanderson.org

UPCOMING EVENTS

<table>
<thead>
<tr>
<th>MAY</th>
<th>JUNE</th>
<th>JULY</th>
<th>OCT.</th>
<th>DEC.</th>
</tr>
</thead>
<tbody>
<tr>
<td>12</td>
<td>11</td>
<td>16</td>
<td>16</td>
<td>1</td>
</tr>
<tr>
<td>Advance Team Annual Meeting</td>
<td>The Brown Foundation Award for Excellence in Oncology Nursing</td>
<td>Making Cancer History® Seminar</td>
<td>Making Cancer History® Seminar</td>
<td>A Conversation With a Living Legend®</td>
</tr>
<tr>
<td>Houston</td>
<td>Houston</td>
<td>Austin</td>
<td>Blowing Rock, N.C.</td>
<td>Aspen, Colo.</td>
</tr>
<tr>
<td>16</td>
<td>25</td>
<td>16</td>
<td>25</td>
<td>1</td>
</tr>
<tr>
<td>Making Cancer History® Seminar</td>
<td>Making Cancer History® Seminar</td>
<td>Making Cancer History® Seminar</td>
<td>Board of Visitors Fall Dinner</td>
<td>Board of Visitors Fall Meeting</td>
</tr>
<tr>
<td>Austin</td>
<td>Blowing Rock, N.C.</td>
<td>Aspen, Colo.</td>
<td>Houston</td>
<td>Houston</td>
</tr>
<tr>
<td>28</td>
<td>29</td>
<td>28</td>
<td>29</td>
<td>1</td>
</tr>
<tr>
<td>Board of Visitors Fall Dinner</td>
<td>Board of Visitors Fall Meeting</td>
<td>Board of Visitors Fall Dinner</td>
<td>Board of Visitors Fall Meeting</td>
<td>Board of Visitors Fall Dinner</td>
</tr>
<tr>
<td>Houston</td>
<td>Houston</td>
<td>Houston</td>
<td>Houston</td>
<td>Dallas</td>
</tr>
</tbody>
</table>

For more information, please visit www.mdanderson.org/gifts or call 800-525-5841. • Download Promise at www.mdanderson.org/Promise.